...
首页> 外文期刊>BMC Urology >Prostate artery embolization has long term efficacy for treatment of severe lower urinary tract symptoms from giant prostatic hyperplasia
【24h】

Prostate artery embolization has long term efficacy for treatment of severe lower urinary tract symptoms from giant prostatic hyperplasia

机译:前列腺动脉栓塞对巨型前列腺增生的严重低尿路症状进行了长期疗效

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Patients with severe lower urinary tract symptoms (LUTS) from giant prostatic hyperplasia (GPH): prostate volume greater than 200?mL that do not respond to medical therapy may not be eligible for surgical treatments due to morbidities, technical challenges, and patient preference. This retrospective investigation examined the long-term efficacy and safety of prostatic arterial embolization (PAE) as a treatment option for severe LUTS due to GPH in a large patient cohort. Of 529 patients who underwent PAE between January 2016 and January 2020, 72 patients had severe LUTS from GPH and were retrospectively evaluated. PAE was performed with two embolic agents in sequence: 100–250?μm particles followed by 2?mm and 3?mm coils. Clinical assessment was performed with international prostate symptoms score (IPSS), quality of life (QoL), peak flow rate (Qmax), post-void residual volume (PVR), and prostate specific antigen (PSA) measurements before and 12?months and 24?months after PAE. Prostate volume (PV) was measured by multiparametric magnetic resonance (MR) imaging before and 12?months and 24?months after PAE. Patients with severe LUTS from GPH experienced significant clinical improvements in IPSS, QoL, Qmax, PVR, PSA, and PV at 12?months and 24?months after PAE. Mean IPSS decreased from 26.5 to 18.0 (P??0.01) to 10.5 (P??0.01). Mean QoL decreased from 6.0 to 4.0 (P??0.01) to 2.0 (P??0.01). Mean Qmax increased from 8.0 to 14?mL/s (P??0.01) to 18?mL/s (P??0.01). Mean PVR decreased from 198.0 to 152.0?mL (P??0.01) to 90?mL (P??0.01). Mean PV decreased from 303.0?mL to 258.0?mL (P??0.01) to 209.0?mL (P??0.01). Mean PSA decreased from 11.2?ng/mL to 9.5?ng/mL (P??0.05) to 7.9?ng/mL (P??0.05). No major complications occurred. PAE is a safe treatment with long term efficacy for severe LUTS from GPH. PAE may be a viable therapeutic option for patients with severe LUTS from GPH whom fail medical therapy and are not candidates for surgical treatments.
机译:来自巨型前列腺增生(GPH)严重尿路症状(LUTS)的患者:前列腺体积大于200?ML,不会响应医疗治疗的含量可能没有资格由于病理挑战,技术挑战和患者偏好而有资格进行手术治疗。这种回顾性研究检测了前列腺动脉栓塞(PAE)作为严重LUT由于GPH的治疗方案的长期疗效和安全性,因为GPH在大型患者队列中。在2016年1月至2020年1月至2020年1月至2020年1月之间的529名患者中,从GPH有严重的LUT,回顾性评估。用两个栓塞剂依次进行PAE:100-250μm粒子,然后是2×mm和3Ωmm的线圈。用国际前列腺症状评分(IPS),寿命质量(QOL),峰值流速(Qmax),空隙后残留体积(PVR)和前列腺特异性抗原(PSA)测量和12个月和12个月和24?PAE后几个月。前列腺体积(PV)通过以前和12个月和12个月和24个月的Multiprametric磁共振(MR)成像测量。来自GPH的严重LUT的患者在12月和24个月和24个月内经历了IPS,QOL,QMAX,PVR,PSA和PV的显着临床改善。平均IPSs从26.5降至18.0(p?<0.01)至10.5(p?<?0.01)。平均QoL从6.0降低到4.0(p?<0.01)至2.0(p?<?0.01)。平均Qmax从8.0增加到8.0至14?ml / s(p?<β01)至18?ml / s(p?<β01)。平均pVR从198.0到152.0?ml(p≤01)至90?ml(p?<β01)。平均光伏从303.0×ml降至258.0×ml(p≤≤0.01)至209.0?ml(p≤0.01)。平均psa从11.2〜ng / ml到9.5 / ml(p?<0.05)至7.9〜ng / ml(p≤0.05)。没有发生重症并发症。 PAE是一种安全的治疗,具有来自GPH的严重LUT的长期疗效。 PAE可以是来自GPH的严重LUT患者的可行治疗选择,谁能失败医疗治疗,并且不是外科治疗的候选者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号